You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 榮昌生物-B(9995.HK)跌逾6%創7個月新低 年內已累跌逾40%
格隆匯 05-25 15:22
格隆匯5月25日丨榮昌生物-B(9995.HK)今日盤中一度跌逾6%至33.6港元,股價創去年10月14日以來逾7個月新低,市值183億港元,該股年內已累跌逾40%。榮昌生物曾發佈一季度業績稱,期內實現營收1.68億元(人民幣,下同),同比增長12.06%;歸母淨虧損由上年同期2.87億元擴大至3.24億元。浦銀國際表示,公司一季度受1月疫情影響,銷售成績或將承受一定壓力,但從3月起明顯反彈。該行認為2Q23的表現對判斷全年業績有重要指引作用。平安證券曾指,2022年醫藥行業上市公司(剔除新股)收入端增速9.59%,歸母淨利潤增速-6.53%;2023Q1醫藥行業上市公司收入端增速為1.51%,歸母淨利潤增速-24.91%。醫藥生物行業2022及23Q1業績受疫情擾動,2023靜候復甦。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account